Company news

Share this article:
Azur Pharma has entered into an agreement with BioSante Pharmaceuticals to acquire US rights to Elestrin, a gel formulation of estradiol indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, for $3.3 million. FDA approved Elestrin in December 2006, and the product is patented through June 2022.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.